论文部分内容阅读
近年来对吸烟的管理是全面的和多方面的,涉及非药物和药物干预。目前常用的戒烟药物疗法包括尼古丁替代治疗、服用盐酸安非他酮等抗抑郁药,但起效温和且有效治疗后的长期戒烟率较低通常在25%～35%,因此,需要新的和有效的方法。伐尼克兰是一种新型尼古丁乙酰胆碱受体部分激动剂。几个随机双盲临床试验已表明,相比已确认的戒烟药安非他酮,伐尼克兰的戒烟率较高。伐尼克兰具有良好的安全性,新的作用机制、更好的疗效和良好的耐受性使酒石酸伐尼克兰成为很有前景的戒烟治疗选择。
The management of smoking in recent years is comprehensive and multifaceted, involving non-drug and drug interventions. Currently used cessation drug therapy, including nicotine replacement therapy, taking anti-depressants such as bupropion hydrochloride, but the onset of mild and effective treatment of long-term smoking cessation rate is usually low in the 25% to 35%, therefore, the need for new and effective method. Varenicline is a novel nicotine acetylcholine receptor partial agonist. Several randomized double-blind clinical trials have shown that varenicline has a higher rate of quitting smoking compared to the bupropion-confirmed bupropion. Varenicline has good safety, a new mechanism of action, better efficacy and better tolerability make varenicline tartrate a promising smoking cessation option.